Eli Lilly to Buy Ajax Therapeutics for Up to $2.3 Billion

Eli Lilly continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker’s blood-cancer portfolio.
Fierce Biotech

Lilly maintains M&A hot streak with $2.3B deal for next-gen JAK inhibitor biotech Ajax

Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax ...

Eli Lilly to buy Ajax Therapeutics for up to $2.3B in cash

Eli Lilly to acquire Ajax Therapeutics for up to $2.3B, boosting blood cancer pipeline with a Phase 1 JAK2 inhibitor for ...

Eli Lilly to Buy Ajax Therapeutics for up to $2.3 Billion in Blood Cancer Bet

April ⁠27 (Reuters) - ⁠Eli ⁠Lilly said ​on ‌Monday ‌it ⁠would ⁠buy privately-held blood ​cancer ​treatment ⁠developer ⁠Ajax ...

Blockx continues ‘dream’ run by eliminating defending champion Ruud in Madrid

Alexander Blockx ’s dream run in Madrid continues. The 21-year-old emerging talent from Belgium has defeated defending ...